IAPS

China Automotive Fragrance and Air Purification Systems Research Report 2023: Driving Wellness Innovations - Exploring the Integration of Fragrance and Air Purification - ResearchAndMarkets.com

Retrieved on: 
Friday, August 18, 2023
Automotive Manufacturing, Manufacturing, Vehicle Technology, Other Automotive, Automotive, GLE, IAPS, Valeo, International, Mercedes-Benz, S class, Filter (signal processing), Geely, Original equipment manufacturer, Symrise, IVI, AMG, CLS, AQS, NIO, Noetics, Toyota, Certification, WM, HVAC, NFC, Plasma, Denso, WeChat, BMW, UV, AIO, XPeng G9, GLS, Highlander, Architecture, Growth, HEPA, Filtration, OEM, Palladium, Rail transport, Heating, ventilation, and air conditioning, Perfume, Civil engineering, Givaudan, Venza

The "China Automotive Fragrance and Air Purification Systems Research Report, 2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "China Automotive Fragrance and Air Purification Systems Research Report, 2023" report has been added to ResearchAndMarkets.com's offering.
  • From 2020 to 2023, the installations of automotive air purification and fragrance systems will sustain steady growth.
  • It is predicted that in 2023 the installations of automotive air purification systems will exceed 6 million units, and that of fragrance systems will reach 1.03 million units.
  • 1.2.2 Principle of Air Purification System: Sources of Pollution and Conventional Purification Process
    1.2.4 Major Air Purification Technologies:

PROFET AI TAKES ON THE WORLD WITH NEW EXPANSION PLANS

Retrieved on: 
Friday, May 19, 2023
IAPS, AUO Corporation, GPT, SoftBank Group, Access, Exhibition, Growth, AI, Medical device

The launch of 'Profet AI Suzhou', a Suzhou, China-based joint venture between Profet AI and Aedgetech, a subsidiary of optoelectronics leader AUO Corporation, was also celebrated at the global event.

Key Points: 
  • The launch of 'Profet AI Suzhou', a Suzhou, China-based joint venture between Profet AI and Aedgetech, a subsidiary of optoelectronics leader AUO Corporation, was also celebrated at the global event.
  • With a target to acquire more than 100 new customers this year, Profet AI continues to expand its global customer base, with a focus on Japan, China, and Southeast Asia
    Profet AI has made Japan a key focus market for its expansion plans.
  • The company also joined the " Pre-Station AI " startup program organized by SoftBank subsidiary Station AI in April 2023.
  • Additionally, Profet AI has launched local partnerships in Japan,   including one with embedded software company Ubiquitous AI , and another to be announced shortly.

Inhibitor of Apoptosis (IAP) Antagonist Drug Pipeline Market Insights Report 2022 Featuring Merck & Co., Novartis, Astex Pharmaceuticals, Ascentage Pharma, & Chia Tai Tianqing Pharmaceutical - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 16, 2022
Health, General Health, IAP, Antagonist, Clinical trial, Neoplasm, Cell death, III, Route, News, T-cell lymphoma, Route of administration, IAPS, Merck & Co., Discovery, II, NDA, XIAP, Acquisition, Inhibitor of apoptosis, Administration, Therapy, Astex, CRT, Head, Patient, Pharmaceutical industry, Vaccine, Merck, Apoptosis

This "Inhibitor Of Apoptosis (IAP) Antagonist- Pipeline Insight, 2022" report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Inhibitor Of Apoptosis (IAP) Antagonist pipeline landscape.

Key Points: 
  • This "Inhibitor Of Apoptosis (IAP) Antagonist- Pipeline Insight, 2022" report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Inhibitor Of Apoptosis (IAP) Antagonist pipeline landscape.
  • The assessment part of the report embraces, in depth Inhibitor of Apoptosis (IAP) Antagonist commercial assessment and clinical assessment of the pipeline products under development.
  • The companies which have their Inhibitor of Apoptosis (IAP) Antagonist drug candidates in the most advanced stage, i.e.
  • phase III include, Merck & Co.
    Inhibitor of Apoptosis (IAP) Antagonist pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

DEBIOPHARM ANNOUNCES ONCOLOGY RESEARCH ADVANCEMENTS AT AACR 2022 FOR NOVEL CANCER COMPOUNDS AND DRUG DELIVERY TECHNOLOGIES

Retrieved on: 
Monday, April 11, 2022
LA, Cell, Company, DAR, Cell cycle, Therapy, Debiopharm, DNA, Neck, CRT, III, DNA repair, Chemoradiotherapy, S phase, Research, Head, G1 phase, WEE1, IAPS, Neurological disorder, Apoptosis, Control, Technology, Safety, G2-M DNA damage checkpoint, Patient, Infection, Vaccine, Pharmaceutical industry, Genome, Merck

LAUSANNE, Switzerland, April 11, 2022 /PRNewswire/ -- Debiopharm, (www.debiopharm.com/debiopharm-international/) an oncology and infectious disease focused biopharmaceutical company based in Switzerland, today announced data releases on 3 investigational products including Debio 0123 (Selective WEE1 inhibitor), clinical exploratory results for xevinapant (IAP inhibitor), and 2 Multilink™ technology posters (antibody drug conjugate linker) at the 2022 Annual American Association for Cancer Research (AACR) meeting in New Orleans, Louisiana. The AACR conference serves as the focal point of the cancer research community to gather together and share advances in oncology science. Debiopharm and their partners' poster presentations represent scientific progress in the research of these compounds leveraging novel modes of action and new delivery methods in development to treat cancer types with high unmet needs.

Key Points: 
  • WEE1 inhibition, particularly in combination with DNA damaging agents, induces DNA breaks leading to the accumulation of DNA damage.
  • This highly effective and well-tolerated linker platform is available for use of other specialty biotech or pharmaceutical companies to generate a proprietary, clinical-stage ADCs.
  • In preclinical studies, xevinapant restored sensitivity to apoptosis in cancer cells, thereby depriving them of one of their major resistance mechanisms to anticancer therapy.
  • Since its establishment in 2015, Genome and Company develops next waves of innovative drugs including anti-cancer microbiome therapeutics and novel target immune checkpoint inhibitors.

DEBIOPHARM ANNOUNCES ONCOLOGY RESEARCH ADVANCEMENTS AT AACR 2022 FOR NOVEL CANCER COMPOUNDS AND DRUG DELIVERY TECHNOLOGIES

Retrieved on: 
Monday, April 11, 2022
LA, Cell, Company, DAR, Cell cycle, Therapy, Debiopharm, DNA, Neck, CRT, III, DNA repair, Chemoradiotherapy, S phase, Research, Head, G1 phase, WEE1, IAPS, Neurological disorder, Apoptosis, Control, Technology, Safety, G2-M DNA damage checkpoint, Patient, Infection, Vaccine, Pharmaceutical industry, Genome, Merck

LAUSANNE, Switzerland, April 11, 2022 /PRNewswire/ -- Debiopharm, (www.debiopharm.com/debiopharm-international/) an oncology and infectious disease focused biopharmaceutical company based in Switzerland, today announced data releases on 3 investigational products including Debio 0123 (Selective WEE1 inhibitor), clinical exploratory results for xevinapant (IAP inhibitor), and 2 Multilink™ technology posters (antibody drug conjugate linker) at the 2022 Annual American Association for Cancer Research (AACR) meeting in New Orleans, Louisiana. The AACR conference serves as the focal point of the cancer research community to gather together and share advances in oncology science. Debiopharm and their partners' poster presentations represent scientific progress in the research of these compounds leveraging novel modes of action and new delivery methods in development to treat cancer types with high unmet needs.

Key Points: 
  • WEE1 inhibition, particularly in combination with DNA damaging agents, induces DNA breaks leading to the accumulation of DNA damage.
  • This highly effective and well-tolerated linker platform is available for use of other specialty biotech or pharmaceutical companies to generate a proprietary, clinical-stage ADCs.
  • In preclinical studies, xevinapant restored sensitivity to apoptosis in cancer cells, thereby depriving them of one of their major resistance mechanisms to anticancer therapy.
  • Since its establishment in 2015, Genome and Company develops next waves of innovative drugs including anti-cancer microbiome therapeutics and novel target immune checkpoint inhibitors.

Aldenham Education Group Brings Current UK Prep School Head, Vicky Gocher, to Riyadh as Founding Head

Retrieved on: 
Sunday, February 20, 2022
Arts Council England, History, KSA, Learning, Family, Time, Headmasters, Silver, Pupil, School, Parent, Education, Curriculum, The Good Schools Guide, AEG, Foundation, CTI Education Group, Leadership, Association, Culture, IAPS, Independent Association of Prep Schools, Artsmark, Headmasters' and Headmistresses' Conference, Partner (business rank), Child, Ageing, Caterham, GCC, Knowledge, Preparatory school, Multimedia, Conference, University of Warwick, HMC, Interior design, Medicine, Tutoring, Management, Aldenham, Charles Gocher

RIYADH, Saudi Arabia, Feb. 20, 2022 /PRNewswire/ -- Aldenham Education Group (Aldenham) is pleased to announce it is bringing Vicky Gocher, current head of Aldenham Prep in the UK, to Riyadh to serve as the Founding Head for the new Aldenham Prep Riyadh in Saudi Arabia. Having led, inspired and educated Aldenham's pupils and teaching staff in the UK for over a decade, the appointment of Gocher as Founding Head will ensure the new Riyadh school is built on the same foundations, principles and ethos as Aldenham in the UK. Opening in September 2022, Aldenham Prep Riyadh will cater to children aged 3-11 years and be the first owner-operated, truly integrated branch campus of a notable independent UK school in Riyadh and the greater GCC region. Announcements for Aldenham Senior School will follow later in the year.

Key Points: 
  • RIYADH, Saudi Arabia, Feb. 20, 2022 /PRNewswire/ --Aldenham Education Group (Aldenham) is pleased to announce it is bringing Vicky Gocher, current head of Aldenham Prep in the UK, to Riyadh to serve as the Founding Head for the new Aldenham Prep Riyadh in Saudi Arabia.
  • Before joining Aldenham, Gocher was previously Deputy Head at Caterham Prep School, a leading, co-educational day school, and holds an MA in Educational Leadership and Innovation from Warwick University.
  • Due to emigrate to the region before starting her new role in September 2022, Gocher shares her delight at founding the Riyadh school: "I am extremely excited to be coming to Saudi Arabia as the Founding Head of Aldenham Prep School Riyadh, after 10 years leading Aldenham Prep School in the UK.
  • Read more about Aldenham Riyadh here: https://www.aldenhamprepriyadh.com/
    Aldenham Education Group (Aldenham or AEG) is the exclusive commercial arm of the Aldenham Foundation, leading all international expansion efforts.

Aldenham Education Group Brings Current UK Prep School Head, Vicky Gocher, to Riyadh as Founding Head

Retrieved on: 
Sunday, February 20, 2022
Arts Council England, History, KSA, Learning, Family, Time, Headmasters, Silver, Pupil, School, Parent, Education, Curriculum, The Good Schools Guide, AEG, Foundation, CTI Education Group, Leadership, Association, Culture, IAPS, Independent Association of Prep Schools, Artsmark, Headmasters' and Headmistresses' Conference, Partner (business rank), Child, Ageing, Caterham, GCC, Knowledge, Preparatory school, Conference, University of Warwick, HMC, Interior design, Medicine, Tutoring, Management, Aldenham, Charles Gocher

RIYADH, Saudi Arabia, Feb. 20, 2022 /PRNewswire/ -- Aldenham Education Group (Aldenham) is pleased to announce it is bringing Vicky Gocher, current head of Aldenham Prep in the UK, to Riyadh to serve as the Founding Head for the new Aldenham Prep Riyadh in Saudi Arabia. Having led, inspired and educated Aldenham's pupils and teaching staff in the UK for over a decade, the appointment of Gocher as Founding Head will ensure the new Riyadh school is built on the same foundations, principles and ethos as Aldenham in the UK. Opening in September 2022, Aldenham Prep Riyadh will cater to children aged 3-11 years and be the first owner-operated, truly integrated branch campus of a notable independent UK school in Riyadh and the greater GCC region. Announcements for Aldenham Senior School will follow later in the year.

Key Points: 
  • RIYADH, Saudi Arabia, Feb. 20, 2022 /PRNewswire/ --Aldenham Education Group (Aldenham) is pleased to announce it is bringing Vicky Gocher, current head of Aldenham Prep in the UK, to Riyadh to serve as the Founding Head for the new Aldenham Prep Riyadh in Saudi Arabia.
  • Before joining Aldenham, Gocher was previously Deputy Head at Caterham Prep School, a leading, co-educational day school, and holds an MA in Educational Leadership and Innovation from Warwick University.
  • Due to emigrate to the region before starting her new role in September 2022, Gocher shares her delight at founding the Riyadh school: "I am extremely excited to be coming to Saudi Arabia as the Founding Head of Aldenham Prep School Riyadh, after 10 years leading Aldenham Prep School in the UK.
  • Read more about Aldenham Riyadh here: https://www.aldenhamprepriyadh.com/
    Aldenham Education Group (Aldenham or AEG) is the exclusive commercial arm of the Aldenham Foundation, leading all international expansion efforts.

Clover and Ascentage Pharma Announce Clinical Collaboration to Evaluate Recombinant Human TRAIL-Trimer Fusion Protein, SCB-313, in Combination with IAP Antagonist, APG-1387 for the Treatment of Peritoneal Carcinomatosis

Retrieved on: 
Thursday, December 9, 2021
MSD, CHB, Vaccine, CEO, DR4, Center, Infection, TRAIL, Severe acute respiratory syndrome coronavirus 2, SCB-2019, Forward-looking statement, GLOBE, IAPS, MD Anderson Cancer Center, Dana–Farber Cancer Institute, Cancer, Patient, Unity Biotechnology, Bladder cancer, National Medical Products Administration, TKI, FTD, SMAC, Degenerative disease, Apoptosis, Priority review, AstraZeneca, Chief executive officer, Biotechnology, The Pauly D Project, Center for Drug Evaluation and Research, NMPA, Therapy, DR5, HBV, California Department of Alcohol and Drug Programs, Safety, Mayo Clinic, Hepatitis, IAP, CpG, ODD, Partnership, Stock exchange, COVID-19, BTD, Treatment, CDE, Malignant pleural effusion, CML, Motherboard, Pharmaceutical industry, Fine chemical

Clover also plans to initiate new Phase 1 trials for SCB-313 in new indications, such as bladder cancer, in 2022.

Key Points: 
  • Clover also plans to initiate new Phase 1 trials for SCB-313 in new indications, such as bladder cancer, in 2022.
  • Discovered and developed by Ascentage Pharma, APG-1387 is a potent and highly specific next-generation IAP antagonist and the first IAP antagonist entering clinical development in China.
  • We hope APG-1387 in combination with Clovers SCB-313 will demonstrate synergistic effect," said Dr. Dajun Yang, Chairman & CEO of Ascentage Pharma.
  • We look forward to working closely with Clover to advance this clinical collaboration which hopefully will offer a new treatment option to patients with peritoneal carcinomatosis.

MegaFans Finds Traction, Milestone, Distributing NFTs and Cryptos for eSports

Retrieved on: 
Wednesday, December 8, 2021
Advertising, Esports, GLOBE, IAPS, Megafan, Community Participation, Mobile, CEO, USD, Non-fungible token, Blockchain, Solution, SAN, Traction, Social media, Video game, Cryptocurrency

"This is a huge milestone for MegaFans," says CEO, Jeff Donnelley.

Key Points: 
  • "This is a huge milestone for MegaFans," says CEO, Jeff Donnelley.
  • "We achieved our goal to surpass break-even economics against ROAS, which makes this a sustainable business model, and we found traction using blockchain solutions and crypto products for our global audience.
  • We couldn't be happier with the results."
  • Launchpool Labs incubator is a 90-day intensive development program focused on building communities and value around startups in the blockchain sector.

Dallas-Based Shokworks Signs With Spain’s eGoGames

Retrieved on: 
Tuesday, September 21, 2021
Data Management, Entertainment, Other Entertainment, Technology, Mobile Entertainment, Software, Electronic Games, CEO, Multimedia, Partnership, Friends, Esports, IAPS, Online gambling, Video game, eGoGames, Shokworks, EGOGAMES, SHOKWORKS

(Photo: Business Wire)

Key Points: 
  • (Photo: Business Wire)
    This game, like all games on the eGoGames mobile esports platform, will be a competitive mobile arena for users across the world.
  • Alejandro Saez, CEO of eGoGames, Europes leading eSports platform for mobile games, is confident this partnership will expand eGoGames footprint into the roughly $20 billion American mobile game market.
  • eGoGames was born to disrupt the mobile game industry, creating a new monetization ecosystem that replaces Ads and IAPs with eSports competitions.
  • Shokworks delivers custom software development and IT consulting services to global startups and enterprise companies looking to embrace digital transformation.